Irving Ford Elected Vice-Chair of PDA's Advanced Therapy Medicinal Products Advisory Board (ATMP AB)

Irving Ford, VP & Head of Quality and Compliance at Made Scientific, has been elected Vice-Chair of the Parenteral Drug Association's (PDA) Advanced Therapy Medicinal Products Advisory Board (ATMP AB), effective July 28, 2026. The board sets strategic direction for PDA on technical and regulatory topics tied to cell, gene, tissue, and other advanced therapy modalities, and plays a key role in shaping industry guidance as the sector continues to scale.

Irving brings more than 30 years of pharmaceutical and biotechnology quality leadership experience to the role. Most recently, as Vice President of Quality at Adaptimmune, he led quality oversight supporting a Biologics License Application (BLA) submission and directed Pre-License Inspection (PLI) readiness across internal and contract manufacturing operations. He previously held senior quality leadership positions at Bristol Myers Squibb and Novartis, where his work supported multiple cell and gene therapy regulatory approvals.

 

At Made Scientific, his leadership centers on inspection readiness, external manufacturing oversight, and strengthening quality organizations to support commercial execution of advanced therapies.

 

“I am grateful to PDA for this opportunity. It's an honor to step into this role at a moment when cell and gene therapies are moving faster than ever from clinical promise to commercial reality,” said Irving Ford. “I look forward to continue working alongside the Advisory Board to help the industry navigate the quality and regulatory challenges that come with successfully bringing ATMPs to patients.”